SCIENTURE HOLDINGS, INC. Fair Value Adjustment of Warrants
SCIENTURE HOLDINGS, INC. (SCNX) reported Fair Value Adjustment of Warrants of -$10.91 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-13
- SCIENTURE HOLDINGS, INC. fair value adjustment of warrants for the quarter ending 2026-06-30 was $0.00.
- SCIENTURE HOLDINGS, INC. fair value adjustment of warrants for the quarter ending 2026-03-31 was -$10.91K.
- SCIENTURE HOLDINGS, INC. fair value adjustment of warrants for the quarter ending 2025-12-31 was -$127.71K.
- SCIENTURE HOLDINGS, INC. fair value adjustment of warrants for the quarter ending 2025-09-30 was -$59.20K.
- SCIENTURE HOLDINGS, INC. fair value adjustment of warrants for fiscal 2025 was -$909.02K, a 596.78% decline from fiscal 2024.
- SCIENTURE HOLDINGS, INC. fair value adjustment of warrants for fiscal 2024 was $182.98K, a 23.29% increase from fiscal 2023.
- SCIENTURE HOLDINGS, INC. fair value adjustment of warrants for fiscal 2023 was $148.42K.
- SCIENTURE HOLDINGS, INC. fair value adjustment of warrants for fiscal 2021 was $21.64K, a 61.96% decline from fiscal 2020.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 3 month as first filed | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$10.91K 10-Q · filed 2026-08-13 | -$138.62K derived: sum of 3 quarters · filed 2026-08-13 | -$197.83K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | -$10.91K 10-Q · filed 2026-05-15 | -$138.62K derived: sum of 2 quarters · filed 2026-05-15 | -$197.83K derived: sum of 3 quarters · filed 2026-05-15 | -$273.95K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | -$127.71K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$186.91K derived: sum of 2 quarters · filed 2026-03-30 | -$263.03K derived: sum of 3 quarters · filed 2026-08-13 | -$909.02K 10-K · filed 2026-03-30 | |
| 2025-09-30 | -$59.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$135.32K derived: sum of 2 quarters · filed 2026-08-13 | -$781.31K 10-Q · filed 2025-11-12 | -$991.17K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | -$76.12K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$722.11K 10-Q · filed 2026-08-13 | -$931.97K derived: sum of 3 quarters · filed 2026-08-13 | -$1.43M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | -$645.99K 10-Q · filed 2026-05-15 | -$855.85K derived: sum of 2 quarters · filed 2026-05-15 | -$1.36M derived: sum of 3 quarters · filed 2026-05-15 | -$1.19M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | -$209.86K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$712.04K derived: sum of 2 quarters · filed 2026-03-30 | -$546.91K derived: sum of 3 quarters · filed 2026-03-30 | $182.98K 10-K · filed 2026-03-30 | |
| 2024-09-30 | -$502.18K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$337.05K derived: sum of 2 quarters · filed 2025-11-12 | $392.84K 10-Q · filed 2025-11-12 | $97.95K derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $165.13K 10-Q · filed 2024-08-09 | $895.02K 10-Q · filed 2025-08-12 | $600.13K derived: sum of 3 quarters · filed 2025-05-12 | $1.53M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2024-03-31 | $729.89K 10-Q · filed 2025-05-12 | $729.90K 10-Q · filed 2024-06-26 | $435.00K derived: sum of 2 quarters · filed 2025-05-12 | $1.36M derived: sum of 3 quarters · filed 2025-05-12 | |
| 2023-12-31 | -$294.89K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $630.43K derived: sum of 2 quarters · filed 2025-03-26 | $148.42K 10-K · filed 2025-03-26 | ||
| 2023-09-30 | $925.32K 10-Q · filed 2024-11-06 | $443.31K 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $1.37M 10-Q · filed 2024-08-09 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $21.64K 10-K · filed 2023-03-27 | |||
| 2021-09-30 | $21.64K 10-Q · filed 2022-11-07 | ||||
| 2020-12-31 | -$92.27K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$43.50K derived: sum of 2 quarters · filed 2022-03-28 | -$22.20K derived: sum of 3 quarters · filed 2022-03-28 | $56.88K 10-K · filed 2022-03-28 | |
| 2020-09-30 | $48.77K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-25 | $70.07K derived: sum of 2 quarters · filed 2021-10-25 | $149.16K 10-Q · filed 2021-10-25 | ||
| 2020-06-30 | $21.29K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-26 | $100.38K 10-Q · filed 2021-07-26 | |||
| 2020-03-31 | $79.09K 10-Q · filed 2021-04-26 | ||||
| 2019-12-31 | $105.45K 10-K · filed 2021-03-29 | ||||
| 2014-12-31 | $374.62K 10-K · filed 2015-03-23 | ||||
| 2013-12-31 | $462.11K 10-K · filed 2015-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |